Pfizer Initiates Study on New Pneumococcal Vaccine for Infants
Pfizer is conducting a study to evaluate the safety and efficacy of a new pneumococcal vaccine (PG4) in infants compared to the existing Prevnar 20® vaccine.
Asset / Drug
Drug and asset intelligence for Infants with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.